Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Receivables: 2010-2021

Historic Receivables for Neurocrine Biosciences (NBIX) over the last 8 years, with Sep 2021 value amounting to $166.6 million.

  • Neurocrine Biosciences' Receivables rose 3.87% to $166.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $639.6 million, marking a year-over-year increase of 7.97%. This contributed to the annual value of $160.8 million for FY2020, which is 27.01% up from last year.
  • As of Q3 2021, Neurocrine Biosciences' Receivables stood at $166.6 million, which was up 3.35% from $161.2 million recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Receivables peaked at $166.6 million during Q3 2021, and registered a low of $6.1 million during Q2 2017.
  • For the 3-year period, Neurocrine Biosciences' Receivables averaged around $137.7 million, with its median value being $152.1 million (2020).
  • As far as peak fluctuations go, Neurocrine Biosciences' Receivables soared by 602.11% in 2018, and later declined by 1.50% in 2021.
  • Neurocrine Biosciences' Receivables (Quarterly) stood at $31.1 million in 2017, then skyrocketed by 84.43% to $57.4 million in 2018, then skyrocketed by 120.53% to $126.6 million in 2019, then climbed by 27.01% to $160.8 million in 2020, then increased by 3.87% to $166.6 million in 2021.
  • Its Receivables was $166.6 million in Q3 2021, compared to $161.2 million in Q2 2021 and $151.0 million in Q1 2021.